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ABSTRACT
Introduction: Evidence shows that treatment
for hepatitis B virus (HBV) can suppress viral
load. Among the factors directly linked to
therapeutic success is adherence to the
treatment. Several instruments to assess
adherence are available, but they are not
validated for use in chronic hepatitis B. The
purpose of this paper was to adapt and validate
the ‘‘Assessment of Adherence to Antiretroviral
Therapy Questionnaire—HIV’’ (CEAT-VIH) for
patients with chronic hepatitis B (referred to
herein as CEAT-HBV).
Methods: The validity of the adapted
questionnaire evidence was established
through concurrent, criterion, and construct
validities.
Results: We found negative and significant
correlation between the domain ‘‘degree of
compliance to antiviral therapy’’ assessed by
CEAT-HBV and the Morisky test (r = -0.62,
P\0.001) and between the domain ‘‘barriers
to adherence’’ and HBV viral load (r = -0.42,
P\0.001). In terms of the construct’s
discriminative capacity, scores greater than or
equal to 80 detected antiviral therapy success,
which are necessary for the prediction of an
undetectable HBV viral load. Thus, a cutoff
value of 80.5 was set with a value of 81% for
sensitivity and 67% for specificity.
Conclusion: The CEAT-HBV identified 43%
(n = 79) non-adherent patients and was shown
to be a useful tool in clinical practice.
Keywords: Assessment tool; Chronic disease;
Hepatitis B; Patient adherence; Questionnaire
INTRODUCTION
Chronic infection caused by hepatitis B virus
(HBV) is an important public health issue [1, 2].
Worldwide it is estimated 240 million people
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are chronically infected [3]. In Brazil, 5441
deaths were reported during the period from
2000 to 2009, with a median of 527.5 deaths per
year and an approximate death rate of 0.3–0.4
per 100,000 habitants [4].
The main objectives of hepatitis B treatment
are to reduce the progression of the hepatic
damage and to eliminate HBV, which
minimizes the conversion to cirrhosis and the
development of hepatocellular carcinoma.
Since several patients do not achieve a
sustained viral response, treatment will usually
last many years, which increases the probability
of selecting resistant viral strains, and
consequently the therapeutic options will be
reduced [5, 6].
Factors such as viral mutations, the reduced
genetic barrier of certain drugs, and the lack of
adherence to antiviral therapy contribute to
drug resistance [7–13]. A few authors have
pointed to adherence to antiviral therapy as a
key point in therapeutic success, which reduces
drug resistance, HBV viral load, and the cost of
treatment [5, 11, 14–16].
Sogni and collaborators demonstrated that
therapeutic education and a systematic
assessment of drug therapy adherence using
self-reporting should be promoted to ensure the
efficacy of a long-term treatment [17]. Thus,
structured questionnaires are the first choice
due to their easy application and low cost [18].
Several self-reported measures for the
assessment of drug treatment adherence are
available. Many instruments are generic in their
scope, such as the Morisky test [18], and others
are only a subjective clinical evaluation by a
health professional [19]. A few address
adherence from a disease-specific perspective
[20, 21, 25, 29]. However, at the time this study
was initiated, a validated questionnaire for
assessing antiviral therapy adherence specific
for chronic hepatitis B was not found in the
literature. As studying the validation of a
specific instrument for this patient group is
essential before investigating probable causes of
non-adherence, we proposed adapting the
‘‘Assessment of Adherence to Antiretroviral
Therapy Questionnaire—HIV’’ (CEAT-VIH) to
assess adherence in HBV-infected patients.
The most important parameter in HBV
treatment is the viral load; however, it is
dependent on a specific laboratory, trained
staff, and equipment. On the other hand,
questionnaires about drug therapy adherence
are low cost and give an immediate answer to
doctors; however, validated questionnaires
regarding adherence to anti-HBV drugs do not
exist. In this context, this work aimed to
describe the adaptation of the CEAT-VIH
questionnaire, developed for assessing
adherence by patients taking HIV
antiretroviral treatment [20, 21]. The option
for this questionnaire was based on the version
in Portuguese, which simplified the process of
adaptation, since the transcultural and
translation for the Brazilian culture were
already done. The original version of this
questionnaire for HIV has been applied by
researchers and health care professionals since
1999 [21].
METHODS
This was a validation study. The target
population was patients with chronic infection
with HBV treated in a public tertiary hospital
reference center. The period of study was
December 2010 to August 2011, and the
sampling was consecutive (not probabilistic).
This research project was approved by the
Institutional Review Board of the Hospital das
Clı´nicas of the University of Sao Paulo School of
Medicine (protocol 0581/10).
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Patients
Inclusion criteria were: both sexes; age
C18 years; clinical diagnosis of chronic
hepatitis B; use of at least 3 months of one or
more anti-HBV antivirals (i.e., adefovir,
entecavir, lamivudine, and tenofovir);
willingness and capacity to answer the
questionnaire; ability to provide written
informed consent; and ability to return for
scheduled treatment and assessment.
Exclusion criteria were: diagnosis of chronic
hepatitis C virus and/or HIV infection.
Each patient was evaluated during one
medical appointment. The protocol consisted
of application of the Morisky test and the
CEAT-HBV. A blood sample for HBV viral load
determination was collected on the same day.
HBV viral load was determined by the COBAS
AmpliPrep-COBAS TaqMan HBV test
(CAP-CTM; Roche Molecular Systems, Inc.,
Branchburg, NJ, USA). The HBV viral load
detection limit was between 54.5 and
110,000,000 IU/mL. The viral load
determination was used in the CEAT-HBV
validation. Socio-demographic data (gender,
age, race, and education), hepatitis B
information, and the patient’s perception
about the antiviral therapy were also collected.
Clinical profile data were obtained from the
physician registration form: HBV viral load,
antiviral drugs in use, and duration of
treatment. All the patients were examined by
two hepatologists and a pharmacist applied the
research questionnaires.
Instrument
The instrument was the validated CEAT-VIH
questionnaire, Portuguese (Brazilian) version,
an instrument with twenty questions that
intends to assess the level of patient adherence
to antiretroviral therapy [20].
Since the Portuguese version of CEAT-VIH
has been shown to be an adequate and effective
tool to verify the level of antiretroviral therapy
adherence in patients with HIV [21], we
proposed to validate this instrument for
patients with chronic hepatitis B, who are also
subject to viral resistance. The adapted version
was called the ‘‘Assessment of Adherence to
Antiviral Therapy Questionnaire’’ (CEAT-HBV).
As a step in the adaptation process of the
CEAT-VIH for the CEAT-HBV, the word ‘‘HIV’’
was replaced by ‘‘hepatitis B’’ in items 8, 10, 15,
and 17. In the other items neither the questions
nor the options for answers were modified [20].
Then, the modified version was reviewed by the
two hepatologists who concluded that this
version could be applied to assess anti-HBV
therapy adherence.
The adapted version, CEAT-HBV, had 20
questions and was divided into two domains.
One domain was called ‘‘degree of compliance
with antiviral therapy’’ with five questions (1–4
and 12). The other domain was called ‘‘barriers
to adherence’’ with the other fifteen questions
(5–11 and 13–20) [22, 23].
The answers to the questions use the 5-point
Likert scale (a higher score indicating greater
adherence to the treatment) except questions 5,
19, and 20. On question 5, the score varies from
zero to two: zero indicates patients who did not
remember the name and dosage of the antiviral
administered; one point for those who knew
only the name or dosage and two points for
those who knew both the name and dosage of
the antiviral. On questions 19 and 20, the score
can be zero or one (a negative answer on
question 19 and an affirmative answer on
question 20 scored one). The full
questionnaire ranges from 17 to 89 points.
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Since there is no gold standard assessment of
antiviral drug adherence, we adopted the
Morisky test [18] to identify the level of
antiviral therapy adherence, from a generic
measure perspective. The original Morisky test
has four items that have dichotomous response
categories with yes or no. The rationale behind
the four items was ‘‘drug errors of omission
could occur in any or all of several ways:
forgetting, carelessness, stopping the drug
when feeling better or starting the drug when
feeling worse’’ [18].
Statistical Analysis
Data were described using mean, standard
deviation, median, minimum and maximum
values and frequency distribution. The Q
Cochran test was used to compare the level of
adherence between the CEAT-HBV, the Morisky
test and clinical outcome (HBV viral load
detectable/undetectable). To evaluate the time
of treatment with antiviral drugs (in months),
patients were classified according to clinical
outcome and adherence to antiviral drug
treatment and the t Student test for
independent samples was applied. To verify
the correlation between the HBV viral load
and time of antiviral drug treatment, the
Pearson coefficient of correlation was
calculated. The questionnaire reliability was
verified using Cronbach’s alpha coefficient
[24]. The construct validation of the
CEAT-HBV was established using concurrent
and criterion validities.
The convergent validation of criterion and
construct was evaluated by a Spearman
correlation between the score on each domain
of the questionnaire (antiviral drug treatment
compliance and barriers to non-adherence) and
the score on the Morisky test and HBV viral
load, respectively. The correlation between the
total score on the CEAT-HBV, the Morisky test,
and HBV viral load was also calculated.
The discriminative capacity was evaluated to
verify if each domain and the full questionnaire
were sensitive to distinguishing the clinical
outcome, i.e., patients with undetectable HBV
viral load. To do this, patients were classified
according to HBV viral load (detectable and
undetectable) in the last 6 months and the
scores for each domain and of the whole
questionnaire were compared using the
Mann–Whitney test. Data were expressed as
median and interquartile range (IQR).
Content validity was determined at the
moment of design of the original
questionnaire, the CEAT-VIH, and was based
on the theoretical model of the instrument [20].
A receiver operating characteristic (ROC)
curve determined the sensibility and specificity
of the CEAT-HBV, and patients were classified
according to HBV viral load (detectable or
undetectable).
Microsoft Excel 2007 (Microsoft
Corporation, Redmond, WA, USA) and SPSS
version 13.0 (IBM Corporation, Armonk, NY,
USA) were used for statistical analyses. The
significance level was set at 0.05.
RESULTS
We screened 580 patients and 230 patients were
registered as taking any antiviral drug for HBV
treatment in the hospital pharmacy. After
applying the inclusion criteria, 183 patients
fulfilled it and comprised the sample in this
study (Fig. 1).
Socio-demographic data on the patients are
depicted in Table 1. Regarding antiviral therapy,
53.6% (n = 98) of patients received lamivudine
as monotherapy, 3.3% (n = 6) received adefovir
as monotherapy, 10.9% (n = 20) received
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tenofovir as monotherapy, 15.3% (n = 28)
received lamivudine and adefovir, and 10.4%
(n = 19) received lamivudine and tenofovir.
The CEAT-HBV presented satisfactory
acceptance as a structured clinical interview.
The minimum and maximum scores were 50 and
89, respectively, and the total median score was
80 (IQR: 77–83). A floor effect was not observed
and the ceiling effect was 0.5% (percentage of
subjects who scored the minimum and
maximum possible score in the questionnaire;
some authors have recommended that it should
be less than 20%) [21, 25].
The reliability for the total questionnaire (20
items, a = 0.73) and in the domain ‘‘degree of
compliance with antiviral therapy’’ (5 items,
a = 0.83) was satisfactory. However, the
reliability of the domain ‘‘barriers to
adherence’’ was less than expected (15 items,
a = 0.66), but was still acceptable.
Fig. 1 Screening of the studied sample
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Construct validity assessed by a concurrent
method showed that the domain ‘‘degree of
compliance with antiviral therapy’’ presented a
moderate and negative correlation with the
Morisky test score (r=-0.62, P\0.001) and the
domain ‘‘barriers to adherence’’ presented a
moderate and negative correlation with HBV
viral load (r=-0.42, P\0.001). The total score
of the CEAT-HBV, indicating global adherence,
alsopresentedamoderateandnegativecorrelation
with the Morisky test (r=-0.44, P\0.001) and
with the HBV viral load (r=-0.47, P\0.001).
The discriminative capacity of the
questionnaire was verified with a comparison
of the scores on the questionnaire (global score
and each domain) that were statistically
different concerning the clinical outcome
(P\0.001; Table 2). There was no intersection
between the IQRs of the CEAT-HBV score
among patients with or without HBV viral
load (P\0.001). Based on this observation, we
established a score of 80 to discriminate
adherent from non-adherent patients.
Assessing the duration of treatment as a
relevant bias for adherence was checked in
patients with (64.1 ± 54.8 months) and
without (70.0 ± 48.3 months) HBV viral load
(P = 0.118). The treatment duration of adherent
patients (determined by a score of 80 on the
CEAT-HBV) was 73.6 ± 50.5 months and of
non-adherent patients 60.0 ± 50.5 months
(P = 0.607). The HBV viral load did not
correlate with antiviral treatment duration
(r = -0.06, P = 0.456).
The CEAT-HBV found 43.2% (n = 79) of
patients were non-adherent. The Morisky test
found 46.4% (n = 85) non-adherent patients
and HBV viral load identified 38.3% (n = 70)
non-adherent patients, without differences
between the methods (P = 0.143).





















Reading and writing only 2.2 (4)
Less than a high school diploma 33.9 (62)
High school 9.3 (17)
Incomplete college 4.4 (8)
College, no degree 19.1 (35)
Incomplete Bachelor´s degree 5.5 (10)
Bachelor´s degree 19.1 (35)
Specialization 2.7 (5)
Data source: Hospital das Clı´nicas of the University of Sao
Paulo School of Medicine, December 2010 to August 2011
(n = 183)
a Mean (standard deviation) age = 52.7 (12.3) years;
range = 18–83 years; median (interquartile range)
age = 54 (45–61) years
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The ROC curve (Fig. 2) for the CEAT-HBV
demonstrated the capacity of the questionnaire
in classifying adherent and non-adherent
patients (P\0.001). We present the sensibility
and specificity of the curve (Table 3) and set the
cutoff at 80.50, which was associated with a
sensibility of 81.4% and a specificity of 67.3%.
DISCUSSION
In the present study, we tested the reliability of
the CEAT-HBV in patients with HBV chronic
infection using different psychometric markers.
The questionnaire presented a satisfactory result
according to parameters established in the
literature [24].
When the hypothesis of the
multi-dimensionality of the questionnaire was
tested with the division of the instrument into
two domains ‘‘degree of compliance with
antiviral therapy’’ and ‘‘barriers to adherence’’,
we verified that the second domain presented a
less than expected internal consistency.
Therefore, the complete questionnaire should
always be used to maintain the psychometric
properties related to reliability.
Both the domain ‘‘degree of compliance with
antiviral therapy’’ and the global adherence
score of the CEAT-HBV presented reliabilities
(a = 0.83 and a = 0.71, respectively) higher than
that of the Morisky test (a = 0.61), which is an
advantage in using CEAT-HBV instead of the
Morisky test.
Table 2 Scores on CEAT-HBV (global score and each domain) with patients stratiﬁed according to HBV viral load
detection, expressed as median and IQRs
Instrument HBV viral load N Median (IQR) P value
Degree of compliance with antiviral therapy Detectable 70 23.0 (21.0–25.0) \0.001
Undetectable 113 25.0 (24.0–25.0)
Barriers to adherence Detectable 70 53.5 (50.0–56.0) \0.001
Undetectable 113 58.0 (55.0–60.0)
CEAT-HBV Detectable 70 77.0 (71.0–79.3) \0.001
Undetectable 113 82.0 (80.0–85.0)
Data source: Hospital das Clı´nicas of the University of Sao Paulo School of Medicine, December 2010 to August 2011
(n = 183)
HBV hepatitis B virus, IQR interquartile range
Fig. 2 Receiver operating characteristic curve of the
CEAT-HBV and sensibility and speciﬁcity indicators.
For the cutoff of 80.50, a sensibility of 81% and speciﬁcity
of 67%. Area under the curve: 80%, P\0.001. Data
source: Hospital das Clı´nicas of the University of Sao
Paulo School of Medicine, December 2010 to August 2011
(n = 183)
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We hypothesized two reasons for the domain
‘‘barriers to adherence’’ presenting an internal
consistency less than 0.70. First, the pattern of
answers in the domain for the current sample
showed a non-normal distribution (i.e.,
asymmetric and leptokurtic distribution) that
Table 3 Cutoff, sensibility and speciﬁcity of CEAT-HBV in patients with chronic hepatitis B virus infection
Criteria % sensibility 95% CI % speciﬁcity 95% CI
\51.50 1.42 0.03–7.70 100.0 96.79–100.0
\56.50 2.85 0.34–9.94 100.0 96.79–100.0
\62.00 4.28 0.89–12.02 100.0 96.79–100.0
\64.50 8.57 3.21–17.73 100.0 96.79–100.0
\66.50 10.00 4.11–19.52 100.0 96.79–100.0
\68.50 11.43 5.06–21.28 99.12 95.17–99.98
\69.50 14.29 7.06–24.71 98.23 93.75–99.78
\70.50 20.00 11.39–31.27 98.23 93.75–99.78
\71.50 25.71 16.01–37.56 98.23 93.75–99.78
\72.50 27.14 17.20–39.10 96.46 91.18–99.03
\73.50 37.14 25.89–49.52 95.58 89.98–98.55
\74.50 40.00 28.47–52.41 93.81 87.65–97.47
\75.50 42.86 31.09–55.25 91.15 84.33–95.67
\76.50 48.57 36.44–60.83 90.27 83.25–95.04
\77.50 61.43 49.03–72.83 85.84 78.03–91.68
\78.50 67.14 54.88–77.90 84.07 76.00–90.28
\79.50 75.71 63.99–85.17 76.99 68.13–84.39
\80.50a 81.43 70.34–89.72 67.26 57.79–75.79
\81.50 81.43 70.34–89.72 55.75 46.11–65.09
\82.50 85.71 75.29–92.93 41.59 32.39–51.24
\83.50 90.00 80.48–95.88 33.63 25.01–43.12
\84.50 92.86 84.11–97.64 26.55 18.68–35.68
\85.50 97.14 90.06–99.65 15.93 9.72–24.00
\86.50 98.57 92.30–99.96 10.62 5.60–17.82
\87.50 100.0 94.87–100.0 3.54 0.97–8.81
\88.50 100.0 94.87–100.0 0.88 0.02–4.83
Data source: Hospital das Clı´nicas of the University of Sao Paulo School of Medicine, December 2010 to August 2011
(n = 183)
CI conﬁdence interval
a Optimal cutoff point
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can affect the reliability coefficient. Second, the
fifteen questions included in this domain could
be harboring more dimensions than proposed
[22], such as the doctor–patient relationship,
collateral effects, perception of the infection,
and others. Future studies can explore this
hypothesis.
An analysis of the reproducibility of a scale
was not performed because the questionnaire
was applied only once to each patient.
Adapting a specific instrument for patients
who live with HIV [20, 26] to the situation of
chronic HBV carriers was proposed initially. The
choice of instrument proposed by Remor and
collaborators [20] was due to its availability in
Portuguese, its validation and content of the
questions of interest, making the unnecessary
translation and cultural adaptation of other
instruments redundant. We considered both
the similarities between these treatments and
the differences, such as the stigma and
psychological impact, thus justifying the
necessity of the adaptation and validation
before application of the CEAT-HBV [27, 28].
As expected, the domains of the CEAT-HBV
presented acceptable construct validity, assessed
by criterion-related and convergent methods,
since there was statistical correlation with
established measures considered gold
standards for these constructs (i.e., the
Morisky test score and HBV viral load).
The analysis of the construct’s discriminative
capacity can be considered satisfactory, since
the total score on the questionnaire was
sufficient to classify patients according to their
viral load level, that is, detectable/
undetectable viral load (P\0.001). However,
in the discriminative capacity of the domains,
we observed an intersection between the IQRs
that showed the necessity of considering the
global score of the questionnaire to evaluate
adherence to the antiviral therapy, as happens
with the original CEAT-VIH [20, 26].
Moreover, we could set a cutoff point on the
global score questionnaire: a score of less than
80 points indicates patients who did not adhere
to antiviral therapy and usually had a
detectable HBV viral load detectable. On the
other hand, a score greater than or equal to 80
points indicates patients who adhered to the
antiviral therapy and usually have an
undetectable HBV viral load.
The CEAT-HBV found 43.2% (n = 79) of
patients were non-adherent. The overview of
adherence studies in hepatitis B showed that the
frequency of adherent patients was between 35
and 74% [16, 29].
The duration of the antiviral therapy could
compromise the validation of the questionnaire
if there were differences between the mean
duration treatment, classified according to the
clinical outcome (HBV viral load detectable or
undetectable) and adherence to treatment (or
non-adherence). This fact could be explained by
the duration needed (generally up to a year) for
patients to present an undetectable HBV viral
load. However, as all the groups presented a
treatment duration longer than 12 months with
a lack of statistical differences, we can state that
these two clinical variables did not compromise
the validation of the questionnaire. The lack of
correlation (r = -0.06, P = 0.456) between HBV
viral load and time of treatment reinforces this
statement.
Patients who were using alpha-interferon or
pegylated interferon were excluded because this
treatment is administered for a limited period of
time and the collateral effects were superior to
those of the antiviral drugs, which would
compromise the questionnaire validation.
The Morisky test presented low reliability in
the present study and poor discriminative
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capacity for clinically related markers. So, this
test identifies many false positives, which is not
unacceptable in a study of adherence to
antiviral therapy due to drug resistance [14,
18]. In contrast, the CEAT-HBV was shown to be
a simple diagnostic tool, useful and easy, and its
use should be widespread in the hepatology
area. As the questionnaire was validated using
the viral load of HBV as the gold standard,
regions with limited financial resources could
use the questionnaire for the early prediction of
outcome. Furthermore, in the present study we
verified that the CEAT-HBV presented greater
sensibility and specificity in comparison to
those reported for the Morisky test (81 and
44%, respectively) [18] and the CEAT-HIV (79
and 57%, respectively) [20]. Other studies have
highlighted the low discriminative capacity of
the Morisky test [30–32].
Poor adherence to antivirals treatment leads
to increased risk of drug resistance and
treatment failure. The present study measured
treatment failure as HBV viral load rebound and
whether the treatment failure is only due to
adherence or development of resistance remains
a question and needs further evaluations.
The response to treatment depends on
factors such as adherence, presence of
resistance and antiviral potency. Entecavir and
tenofovir are more potent antivirals with high
genetic barrier to resistance; therefore, it is
possible that patients with non-adherence
would need longer time to observe treatment
failure [15].
In this study, the results showed that an
instrument proposed for patients with HIV can
be used for patients with chronic HBV. It is
noteworthy to mention that the adherence is
fully monitored in randomized controlled trials,
which brings curiosity about the patients’
behavior concerning adherence in real life, as
observed by recent researchers [5, 16, 17].
CONCLUSIONS
CEAT-HBV is an instrument with adequate
reliability, validity, and discriminative
capacity. It is adequate to assess the adherence
to antiviral therapy and predict the clinical
outcome of the patient (HBV viral load
detectability), making it a valuable tool in
clinical practice. Furthermore, it is the first
specific instrument suitable for the evaluation
of antiviral treatment adherence in patients
with chronic HBV; however, more studies
about the advantages and disadvantages of
each instrument should be conducted. At this
time, it seems appropriate to recommend the
CEAT-HBV as a useful tool for the doctor in
clinical practice with patient non-responders to
antiviral drug treatment, as a first step toward
improving antiviral therapy adherence, which is
considered a key factor for therapeutic success.
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